New hope for tough colorectal cancer: Triple-Drug combo enters human trials
Disease control
Not yet recruiting
This study tests a combination of three drugs—S-531011, fruquintinib, and pembrolizumab—in people with advanced colorectal cancer that has not responded to standard treatments. The cancer type is called MSS or pMMR, which typically does not respond well to immunotherapy alone. Th…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC